Quantitative EHV-1 Biomarkers for Horse Immunity and Infection Staging
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for Equine herpesvirus 1 (EHV-1) infections in horses do not differentiate between susceptible and immune horses, leading to unnecessary quarantine of immune horses and inefficient vaccination schemes, which increase costs and time during outbreaks.
Innovation Solution
The use of biomarkers such as EHV-1 specific IgG1, IgG4/7, IFN-α, CCL3, CCL2, and sCD14 in nasal and serum samples to determine the stage of infection and immunity status, allowing for informed management decisions and optimized vaccination strategies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If PCR is used to diagnose EHV-1 infections, then sensitivity of detection is improved, but inability to distinguish immune from susceptible horses leads to unnecessary quarantine and increased costs
Solution Approach 1:
The diagnostic approach is segmented into two independent detection components: PCR for viral DNA detection and ELISA for antibody titer detection. This segmentation allows each test to perform its specialized function - PCR identifies presence of viral genetic material while ELISA quantifies immune response, together providing comprehensive diagnostic information that neither test could provide alone.
Solution Approach 2:
Antibody titers serve as an intermediary indicator of immunity status. Rather than directly measuring immune cell functionality, the patent uses quantifiable antibody levels (IgG1, IgG3, IgG4) as a surrogate marker to infer protective immunity status, enabling indirect assessment of immune protection without complex cellular assays.
2Reliability
If all horses are quarantined based on PCR results, then outbreak control is ensured, but immune horses experience unnecessary quarantine time and economic loss
Solution Approach 1:
Quarantine measures are differentiated based on individual horse immunity status rather than applying uniform quarantine to all horses. Horses with high antibody titers (≥1:640) receive localized exemption from quarantine, while horses with low titers undergo standard quarantine. This localized quality approach maintains outbreak control reliability while reducing unnecessary time loss for protected animals.
Solution Approach 2:
The diagnostic threshold parameter for antibody titers is optimized to balance sensitivity and specificity. By setting the cutoff at ≥1:640, the system identifies horses with sufficient protective immunity to safely exclude from quarantine, while maintaining stringent criteria to ensure true protected horses are identified, thus optimizing the balance between reducing quarantine time and maintaining outbreak control.
3Reliability
If vaccination is administered every six months, then immunity coverage is maintained, but lack of rational research support leads to possible unnecessary or inefficient vaccination schemes
Solution Approach 1:
The patent implements feedback-based vaccination decision making through regular antibody titer monitoring. Instead of fixed-schedule vaccination, horses are tested periodically and vaccination is administered only when titers fall below protective thresholds. This feedback loop optimizes vaccination timing based on actual immune status, eliminating unnecessary vaccinations while maintaining protective coverage.
Solution Approach 2:
The patent applies partial action by administering vaccination only to horses that require it based on titer levels, rather than vaccinating all horses on a fixed schedule. This selective approach reduces unnecessary vaccination procedures while ensuring adequate coverage is maintained in horses that have lost protective immunity, improving overall vaccination efficiency.
Data Source
AI summary
The present disclosure is directed to novel biomarkers useful for staging EHV-1 infections and immunity status of horses. This disclosure is further directed to methods of determining EHV-1 infection stage and immunity status of horses using the novel biomarkers.